1e
19
1
49
2
2
18
1b
1d
18
39
63
1d
2 29
1d
25
Vincent Lo Re III, MD, MSCE
78
63
Emeritus Associate Professor of Medicine (Infectious Diseases)
28
a7
3
5f
Attending Physician, Infectious Diseases Section, Medicine Service, Philadelphia Veterans Affairs Medical Center
8a
Attending Physician, Infectious Diseases Division, Penn Presbyterian Medical Center
ad
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
7
9f
Attending Physician, Center for Viral Hepatitis, Perelman School of Medicine, University of Pennsylvania
95
Co-Director, NIGMS-funded T32 Pharmacoepidemiology Training Grant, Perelman School of Medicine
bc
Investigator, Center for Real-World Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania
ea
Co-Director, Master of Science in Clinical Epidemiology Degree Program, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
11
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
71
4
3
3
1d
71
Rutgers Institute for Health, Health Care Policy and Aging Research
42 112 Paterson Street, Room 353M
New Brunswick, NJ 08901
26
42 112 Paterson Street, Room 353M
New Brunswick, NJ 08901
35
f
18
Publications
23 a
3
2
29
23 a
Links
c9 Search PubMed for articles
a2 Center for Clinical Epidemiology and Biostatistics faculty webpage.
c
4
b
1f
c9 Search PubMed for articles
a2 Center for Clinical Epidemiology and Biostatistics faculty webpage.
c
13
Education:
21 9 B.S. 16 (Chemistry) c
2e Georgetown University, 1992.
21 9 M.D. 15 (Medicine) c
33 University of Pennsylvania, 1997.
21 d M.S.C.E. 21 (Pharmacoepidemiology) c
33 University of Pennsylvania, 2005.
c
3
3
3
3
8a
Permanent link21 9 B.S. 16 (Chemistry) c
2e Georgetown University, 1992.
21 9 M.D. 15 (Medicine) c
33 University of Pennsylvania, 1997.
21 d M.S.C.E. 21 (Pharmacoepidemiology) c
33 University of Pennsylvania, 2005.
c
2 29
21
1e
1d
24
5e
77 - Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
30 - Adherence to hepatitis C virus therapy
27 - Hepatotoxicity of medications
29 - Evaluation of clinical outcomes
37 - Population-based and administrative databases
8
18 Key Words
82 HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology
8
26 Description of Research
2ed Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.
8
1f2 Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.
8
b2 Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.
65
1a 29
27
Description of Research Expertise
2a Research Interests77 - Hepatic and non-hepatic outcomes of chronic hepatitis B and C, particularly among patients with HIV infection
30 - Adherence to hepatitis C virus therapy
27 - Hepatotoxicity of medications
29 - Evaluation of clinical outcomes
37 - Population-based and administrative databases
8
18 Key Words
82 HIV/viral hepatitis coinfection; hepatitis B; hepatitis C; HIV/AIDS; epidemiology; clinical outcomes; pharmacoepidemiology
8
26 Description of Research
2ed Dr. Lo Re’s research focuses on clinical outcomes of chronic viral hepatitis infection in HIV-infected patients. He is conducting epidemiologic studies to examine novel risk factors for decompensated cirrhosis among HIV/hepatitis C-coinfected patients and is working to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C patients according to their risk of progression to hepatic decompensation. He has also examined the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients. Additional studies are examining non-hepatic outcomes of chronic viral hepatitis infection in HIV, particularly abnormalities in bone mineral density and fractures.
8
1f2 Dr. Lo Re also evaluates clinical outcomes of hepatitis therapy in the setting of HIV. Recent work has examined the incidence and risks factors for anemia and weight loss during hepatitis C therapy among HIV-infected patients. Another active area of research is adherence to combination pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.
8
b2 Methodologic interests include use of population-based databases for epidemiologic research, ascertainment and adjudication of clinical outcomes, and pharmacoepidemiology.
65
Description of Clinical Expertise
74 Viral hepatitis; HIV/hepatitis C coinfection; HIV/hepatitis B coinfection; drug-induced liver injury1a 29
23
198 Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
146 Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd: Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 15(2): e0228471, February 2020.
129 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: Determinants of stigma among patients with hepatitis C virus (HCV) infection. J Viral Hepat 27(11): 1179-89, November 2020.
18d Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd: HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst 112(7): 747-755, July 2020.
1da Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd: Risk of hepatocellular carcinoma with hepatitis B viremia among HIV/HBV-coinfected persons in North America. Hepatology 74(3): 1190-1202, September 2021.
d8 Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd ce : PI-based HCV DAAs are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 75(6): 1312-1322, December 2021.
11d Weinstein EJ, Ritchey ME, Lo Re V 3rd: Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real-world healthcare databases. Pharmacoepidemiol Drug Saf 32(1): 1-8, January 2023.
1f5 Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM: Association of COVID-19 versus influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 328(7): 637-51, August 2022.
175 Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman JR, Trooskin SB, Lo Re V 3rd: The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially-insured population. Open Forum Infect Dis 9(9): ofac445, September 2022.
2c
7
1d
1f
Selected Publications
1e5 Lo Re V 3rd, Kallan MJ, Tate J, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC: Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 160(6): 369-79, March 2014.198 Goldberg DS, Forde KA, Haynes K, Lewis JD, Carbonari DM, Leidl KBF, Nezamzadeh MS, Reddy KR, Roy J, Sha D, Marks AR, De Boer J, Strom BL, Corley DA, Lo Re V 3rd: Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 148(7): 1353-61, June 2015.
146 Saine ME, Moore TM, Szymczak JE, Bamford LP, Barg FK, Mitra N, Schnittker J, Holmes JH, Lo Re V 3rd: Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. PLoS One 15(2): e0228471, February 2020.
129 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd: Determinants of stigma among patients with hepatitis C virus (HCV) infection. J Viral Hepat 27(11): 1179-89, November 2020.
18d Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Lo Re V 3rd: HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst 112(7): 747-755, July 2020.
1da Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Sun J, Hull M, Gill MJ, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd: Risk of hepatocellular carcinoma with hepatitis B viremia among HIV/HBV-coinfected persons in North America. Hepatology 74(3): 1190-1202, September 2021.
d8 Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V 3rd ce : PI-based HCV DAAs are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 75(6): 1312-1322, December 2021.
11d Weinstein EJ, Ritchey ME, Lo Re V 3rd: Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real-world healthcare databases. Pharmacoepidemiol Drug Saf 32(1): 1-8, January 2023.
1f5 Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, Hubbard RA, Kempner ME, Kuntz JL, McMahill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM: Association of COVID-19 versus influenza with risk of arterial and venous thrombotic events among hospitalized patients. JAMA 328(7): 637-51, August 2022.
175 Ferrante ND, Newcomb CW, Forde KA, Leonard CE, Torgersen J, Linas BP, Rowan SE, Wyles DL, Kostman JR, Trooskin SB, Lo Re V 3rd: The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially-insured population. Open Forum Infect Dis 9(9): ofac445, September 2022.
2c